Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia

Nature Medicine volume 21, pages 113–114 (2015)Cite this article

Subjects

Pathogenic mutations of the genes encoding isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) occur in people with acute myeloid leukemia or other tumors. A new study identifies a dependence of IDH-mutated cells on the anti-apoptosis regulator BCL-2 and indicates a 'synthetic lethal' strategy for the treatment of leukemias.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Synthetic lethal mechanism of mutant IDH and BCL2 inhibition.

Marina Corral Spence/Nature Publishing Group

References

  1. Parsons, D.W. et al. Science 321, 1807–1812 (2008).

    Article  CAS  Google Scholar 

  2. Mardis, E.R. et al. N. Engl. J. Med. 361, 1058–1066 (2009).

    Article  CAS  Google Scholar 

  3. Dang, L. et al. Nature 462, 739–744 (2009).

    Article  CAS  Google Scholar 

  4. Ward, P.S. et al. Cancer Cell 17, 225–234 (2010).

    Article  CAS  Google Scholar 

  5. Figueroa, M.E. et al. Cancer Cell 18, 553–567 (2010).

    Article  CAS  Google Scholar 

  6. Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R. Proc. Natl. Acad. Sci. USA 111, 2548–2553 (2014).

    Article  CAS  Google Scholar 

  7. Pandolfi, A., Barreyro, L. & Steidl, U. Stem Cells Transl. Med. 2, 143–150 (2013).

    Article  CAS  Google Scholar 

  8. Wang, F. et al. Science 340, 622–626 (2013).

    Article  CAS  Google Scholar 

  9. Rohle, D. et al. Science 340, 626–630 (2013).

    Article  CAS  Google Scholar 

  10. Chan, M. et al. Nat. Med. 21, 178–184 (2015).

    Article  CAS  Google Scholar 

  11. Souers, A.J. et al. Nat. Med. 19, 202–208 (2013).

    Article  CAS  Google Scholar 

  12. da Silva, C.G. et al. Biochim. Biophys. Acta 1586, 81–91 (2002).

    Article  CAS  Google Scholar 

  13. Latini, A. et al. Mol. Genet. Metab. 86, 188–199 (2005).

    Article  CAS  Google Scholar 

  14. Larman, T.C. et al. Proc. Natl. Acad. Sci. USA 109, 14087–14091 (2012).

    Article  CAS  Google Scholar 

  15. Silkjaer, T. et al. Eur. J. Haematol. 90, 385–396 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Amit Verma is in the Department of Medicine (Oncology), Division of Hemato-Oncology; the Department of Developmental and Molecular Biology; the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research; and the Albert Einstein Cancer Center, Albert Einstein College of Medicine/Montefiore Medical Center, New York, New York, USA.,

    Amit Verma

  2. the Department of Developmental and Molecular Biology,

    Amit Verma

  3. Ulrich Steidl is in the Department of Cell Biology; the Department of Medicine (Oncology), Division of Hemato-Oncology; the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research; and the Albert Einstein Cancer Center, Albert Einstein College of Medicine/Montefiore Medical Center, New York, New York, USA.,

    Ulrich Steidl

  4. the Department of Medicine (Oncology), Division of Hemato-Oncology,

    Ulrich Steidl

Authors
  1. Amit Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Steidl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Steidl.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Verma, A., Steidl, U. A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia. Nat Med 21, 113–114 (2015). https://doi.org/10.1038/nm.3796

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3796

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer